In an evolution of Networking Meetings aimed at meeting the need to bring leading edge scientists together with industry experts and collaborators in order to enhance the translational research interface, this event will be a game of two halves. A scientific session will update attendees on what’s in the pipeline for next generation biologics and followed by a session covering recent approvals and pitfalls in the commercial success of biosimilars and Q&A about the future opportunities for this region.

Programme:

16.15 Delegate registration and networking
16.45 Welcome from the Host and Chair
17.00 Advances in Protein Engineering Science in the Design of New Medicines, Speaker TBC
17.30 Minimising Therapeutic Antibody Immunogenicity, Dr Matthew Baker, CSO, Abzena
18.00 Refreshments and Tour of Terminal
18.30 Opportunities and Pitfalls in Biosimilar Development and Commercialisation
18.30 Commercial Considerations for Biosimilar Developers, Sahar Shepperd, Partner, Bristows LLP
18.40 Regulatory and Legal Considerations Relating to Biosimilars, Dominic Adair, Partner, Bristows LLP
18.50 Case Study Presentation
19.00 Q&A Discussion: Can the UK retain an innovation advantage in protein engineered drugs?
19.25 Closing remarks from the Chair
19.30 Networking, drinks and canapes
20.30 Close

Prices:

Gold Member 3 free delegates then £40.00 + VAT for additional delegates
Silver Member 3 free delegates then £40.00 + VAT for additional delegates
Academia Contact Nadia on nadia@onenucleus.com for free registration.
Non-member £150 + VAT

MediWales members receive 10% discount to attend

View more information here